Is Traws Pharma Inc (TRAW) overvalued? · rev $226.0K
Traws Pharma Inc (TRAW) is a biotechnology company listed on NASDAQ.
This page asks whether Traws Pharma Inc (TRAW) looks expensive on cached numbers — not a short thesis.
Latest reported TRAW revenue for 2024-12-31 was $226.0K. Net income was -$166.5M. Revenue was up 0.0% from 2023-12-31 to 2024-12-31. TRAW currently screens at market cap $12.1M.
TRAW currently screens at market cap $12.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TRAW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TRAW stock page for the full model, not this heading.
Not investment advice.